Clinical Trial Update: Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery [Phase 1]

View source ↗

Summary

A Phase 1 study of pazopanib in patients with newly diagnosed or surgically removable locally/regionally recurrent breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Male Breast Carcinoma, Recurrent Breast Carcinoma | Phase 1 | Status: TERMINATED